3.3800 +0.07 (2.11%)
Before hours: 9:23AM EDT
|Bid||2.9700 x 1200|
|Ask||3.5500 x 800|
|Day's Range||3.2100 - 3.4200|
|52 Week Range||0.5020 - 5.3500|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||9.40|
|Earnings Date||Aug 12, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.27|
cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBD PR A) (the "Company"), one of the leading, and most highly trusted and recognized cannabidiol (CBD) brands, announced today that it is expanding its exclusive CBD partnership with 12-Time PGA Tour Winner and Two-Time Masters Champion Bubba Watson. The partnership will continue through the end of 2022 and includes prominent logo display and collaboration both on and off the golf course. Bubba will serve as a main headliner of the brand’s premier athletic sponsorship program, "Team cbdMD," within its upcoming marketing and advertising campaigns.
cbdMD, Inc. (NYSE American: YCBD, YCBD PR A ), one of the leading, and most highly trusted and recognized, cannabidiol (CBD) brands, announced today that it will host a conference call at 4:15 p.m., Eastern Time, on Wednesday, August 12, 2020, to discuss the company’s third quarter of fiscal 2020 financial results and business progress.
cbdMD, Inc. (NYSE American: YCBD, YCBD PR A) (the "Company"), one of the leading, and most highly trusted and recognized, cannabidiol (CBD) brands, announced today that it is extending its category-exclusive Official CBD marketing partnership with Bellator MMA, a wholly owned subsidiary of ViacomCBS. As part of the agreement, the cbdMD brand will be prominently featured on the mat at all Bellator MMA fights and throughout all Bellator MMA social media content.
cbdMD, Inc. (NYSE American: YCBD, YCBD PR A), one of the leading, most trusted and most recognized cannabidiol (CBD) consumer brands, announced today that it has filed a new patent application with the U.S. Patent and Trademark Office which will allow it to pursue patented protection in several key areas, including novel formulations and delivery systems, as well as methods of manufacturing and use. The recent submission by the company is part of its ongoing intellectual property strategy to ensure appropriate protection around its product lines and to be forward-thinking as to the direction of the CBD market.
cbdMD, Inc., a nationally recognized, hemp derived, consumer cannabidiol (CBD) brand (NYSE American: YCBD, YCBD PR A), announced today that Marty Sumichrast, its Chairman and co-CEO, and Ken Cohn, its Chief Marketing Officer, will participate in a virtual ‘fireside’ chat on July 10, 2020 beginning 10:30 a.m. EDT which is part of Alliance Global Partners’ series ‘The Cannabis Chronicles.’
cbdMD, Inc. (NYSE American: YCBD, YCBD PR A) (the "Company"), one of the leading, highly trusted, and most recognized cannabidiol (CBD) brands, reported today its second fiscal 2020 quarter ended March 31, 2020 results, as well as some significant developments, the highlights of which were:
cbdMD, Inc. (NYSE American: YCBD, YCBD PR A ), a nationally recognized consumer cannabidiol (CBD) brand, announced today that it will host a conference call at 4:15 p.m., Eastern Time, on Monday, May 18, 2020, to discuss the company’s second quarter of fiscal 2020 financial results and business progress.
CBD Industries, LLC, the wholly owned manufacturing and distribution subsidiary of cbdMD, Inc., a nationally recognized consumer cannabidiol (CBD) brand (NYSE American: YCBD, YCBD PR A), was recently added to NSF International’s dietary supplements Good Manufacturing Practice (GMP) registration. GMPs are guidelines that provide a system of processes, procedures and documentation to assure a product has the identity, strength, composition, quality and purity that appear on its label. In September 2019 NSF International announced it had begun providing a wide variety of independent testing, verification, auditing and certification services to manufacturers of consumer products containing hemp and hemp-derived CBD. NSF International independently registers manufacturers as meeting GMP requirements.
The U.S. CBD sector held so much promise after the government approved the 2018 Farm Bill. Market research firms stared placing total addressable market targets topping $20 billion in a few years, but the FDA has left the market to mostly just lotions and creams leaving the high demand products off major retailer shelves.At the same time, thousands of different brands have flooded to the space including ones from the large Canadian cannabis LPs. Both Aurora Cannabis and Canopy Growth, amongst others, have launched brands in the U.S. due to CBD being legal in the U.S pushing the brand totals above 2,000.CBD is the non-psychedelic version of marijuana associated with health and wellness products. Unfortunately for the market segment, the FDA has a mandate to require testing on food products declassified as a Schedule I drug. CBD falls into this category and the majority of the potential sales boost from CBD is tied into ingestible products like foods, dietary supplements and beverages.The sector is left mostly selling lotions and topical creams where product demand is normally around 15% of the total market demand. For the most part, mass retailers haven’t been willing to take on products under regulatory scrutiny by the FDA. The market once targeted at $20 billion in sales is now forecast by BDS to reach $12.3 billion in 2022 while Jefferies only predicts a market of $3.5 billion as the current pace and regulatory dynamics limits growth.The key here is that the related CBD stocks are now appropriately beaten down for the worse case scenario. The positive news from the coronavirus outbreak is that medical cannabis was considered essential in a sign that the regulators and governments continue to view cannabis products as essential parts of life leading to speculation the U.S. federal government will approve regulation allowing the expanded sales of CBD by requiring the FDA to remove any restrictions will pushing forward with testing.We’ve delved into three stocks set to benefit from ramped-up sales in CBD space. Using TipRanks’ Stock Comparison tool, we lined up the three alongside each other to get the lowdown on what the near-term holds for these CBD players.Canopy Growth (CGC)Canopy Growth is the new play in the space. Originally, the large Canadian was wasting money heading into the crowded U.S. cannabis space, but now the space is largely fragmented and likely to lose a ton of smaller players during the economic shutdown.Some of the estimates of the U.S. CBD market space alone match or even exceed the cannabis space in Canada. Canopy's first and foremost product has a better opportunity to grab shelf space now and the company could use their balance sheet to purchase some struggling players in the industry on the cheap. Similar to the Abacus Health acquisition by CWH, Canopy Growth could easily snap up some CBD brands in the U.S. on weakness and spend far below $100 million.At $14.50, the company only has a market cap of $5 billion with FY21 revenue estimates of $500 million. When Canopy Growth was originally forecasting 2020 sales topping $1 billion, the U.S. CBD market appeared more of a distracting move by the company. Now, a sudden removal of FDA restrictions could actually make the CBD product a prime revenue generator of the business.Canopy Growth was already a buy in the low teens and a big boost in the CBD space will magnify the market opportunity. The large Canadian player has far more capital to thrive via a protracted tough regulatory environment.TipRanks points to analyst sentiment split between confidence and caution on Canopy Growth shares. Out of 13 analysts polled in the last 12 months, 6 rates CGC a Buy, 6 say Hold, while only 1 suggests Sell. However, the consensus average price target stands at $20.86, marking a 43% upside potential from current levels. (See Canopy stock analysis on TipRanks)Charlotte’s Web Holdings (CWBHF)The ultimate signal for the health in the sector is Charlotte’s Web Holdings. The company is the clear independent leader in the U.S. CBD space and the stock hit a new 52-week low below $3 in March.The stock now has a market cap below $500 million while the original sales goal for this year was $350 million. Analysts even forecast 2021 sales topping $500 million as recently as mid-2019.Any signs of health in the CBD sector will first be seen via a boost in the stock price of CWH and the quarterly results. With the acquisition of Abacus Health Products, the company has access to over 15,000 unique retail doors plus some 16,500 health provider offices to expand distribution and consolidate market leadership in the space.CWH just needs the FDA to clear up the regulatory uncertainty surrounding food products and business will soar. H.R. 5587 would amend the Food, Drug, and Cosmetic Act to remove the requirements placing regulatory restrictions on food products. The new company will only trade at ~1x sales estimates once the FDA relaxes regulations.With 3 recent Buy ratings under its belt, CWH gets a Strong Buy from the analyst consensus view. The stock is a bargain at $4 and with an average price target of $7.31, an 81% twelve-month rise could be in the cards. (See CWH stock analysis on TipRanks)cbdMD (YCBD)cbdMD continues to trade near all-time lows below $1 following preliminary FQ2 numbers. The company focused on CBD sales saw revenues hit $9.4 million in the quarter, as sales were hit by the FDM mass market where the Covid-19 pandemic impacted sales.The company operates under the cbdMD and Paw CBD brands with a high reliance on influencers to sell products via their e-commerce site. While cbdMD expanded to over 5,300 retail doors, total tales were still driven predominantly by their e-commerce channel with over 70% of FQ2 sales from this channel.As with other CBD focused players, the company generates gross margins in the 65% range. Unfortunately, cbdMD has to spend $5 million in the marketing and sales area in order to drive sales leading to a net loss of about $5.1 million in the prior quarter after stripping out non-cash charges.The company has an improved cash balance of $14.5 million at the end of March. The stock is the speculative play of the group with investors buying this stock in a scenario where the FDA relaxes regulations on CBD food products sooner rather than later.To find good ideas for cannabis stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
CHARLOTTE, NC / ACCESSWIRE / April 9, 2020 / cbdMD, Inc. (NYSE American:YCBD, YCBD PR A) today announced that the location of its 2020 annual meeting of shareholders will be changed from an in person meeting to a virtual format. The 2020 annual meeting of shareholders, which was previously announced in cbdMD's Notice of 2020 Annual Meeting of Shareholders and Proxy Statement and filed with the Securities and Exchange Commission ("SEC") on March 11, 2020, and originally mailed to shareholders on or about March 11, 2020, will still be held on April 23, 2020 beginning at 1:00 p.m. Eastern time, but in a virtual meeting format only, available at https://www.issuerdirect.com/virtual-event/ycbd. Due to the emerging public health impact of the Covid-19 pandemic, the "stay at home" order issued on March 27, 2020 by the Governor of the State of North Carolina where cbdMD's offices are located, and to support the health and well-being of cbdMD's employees, shareholders, and partners, cbdMD has decided to hold the 2020 annual meeting of shareholders in a virtual meeting format only.
cbdMD, Inc. (NYSE American: YCBD, YCBD PR A), a leading cannabidiol (CBD) consumer brand, announced today that in the coming weeks, cbdMD intends to offer third party manufactured single use alcohol-based hand sanitizers (which will not contain CBD) free with the purchase of cbdMD products, while supplies last. Details will be available on cbdMD.com.
cbdMD, Inc. (NYSE American: YCBD, YCBD PR A), a leading cannabidiol (CBD) consumer brand, announced today that its preliminary year over year sales for the second quarter of fiscal 2020 ended March 31, 2020 grew 167% to approximately $9.4 million from its second quarter fiscal 2019 quarterly sales of $5.64 million.
cbdMD, Inc. (NYSE American: YCBD, YCBD PR A), a leading cannabidiol (CBD) consumer brand, provided the following corporate message from Chairman Martin Sumichrast.
cbdMD, Inc., a nationally recognized consumer cannabidiol (CBD) brand (NYSE American: YCBD), is set to launch their new line of CBD PM Softgel Capsules in conjunction with World Sleep Day (March 13). Utilizing their unique Superior Broad Spectrum formula, cbdMD’s latest offering includes the same proprietary sleep formula with ingredients like melatonin, chamomile, valerian root, and more.
Better Choice Company, Inc. (BTTR) (the “Company” or “Better Choice”), an animal health and wellness company, today announced the execution of a non binding letter of intent to form a joint venture (“JV”) with cbdMD, Inc. (NYSE American: YCBD, YCBD PR A), a leading cannabidiol (CBD) consumer brand. Subject to the negotiation and execution of definitive agreements both parties intend to contribute certain CBD animal health related assets, including brands, CBD supply, logistics, service agreements, intellectual property, back office support and other assets with the mutual goal of expanding their respective hemp derived CBD pet brands, in exchange for 50% ownership in the newly formed JV.
cbdMD, Inc. a nationally recognized consumer cannabidiol (CBD) brand (NYSE American: YCBD), is pleased to announce that their CBD PM and CBD Freeze products have been voted the winner of the prestigious 2020 Product of the Year award in the CBD Sleep Aid and CBD Topical categories, respectively.
While the U.S. Federal government doesn’t appear any closer to approving cannabis, Congress does appear set to tackle the regulations holding back widescale sales of cannabidiol or CBD. The passage of the 2018 Agriculture Improvement Act (farm bill) legalized hemp production setting the market up for a strong sales ramp, but the U.S Food and Drug Administration squashed the growth opportunity by blocking CBD used as dietary supplements.Hemp contains less than 0.3% of tetrahydrocannabinol (THC), whereas marijuana contains up to 30% of the psychoactive compound. CBD is increasingly presumed to contain properties for wellness and pain management increasing the attractiveness of hemp-infused CBD products. Unfortunately for the market, the FDA continues to question the lack of safety research on CBD products and placed into question the approval of edibles.For this reason, the large proclamations for huge CBD sales have taken a hit. National retailers haven’t stocked edible products due to the potential ire of the FDA causing pure CBD companies to miss sales targets in 2019.The industry has high expectations for substantial sales with the FDA eventually allowing CBD in food and supplements. Combined research from Roth Capital Partners, Brightfield Group and Cowen predicted a CBD market of ~$17 billion with Roth predicting a market potential to achieve sales in the $40 billon range.Last week, Congress appeared to have wide support for H. R. 5587. The bill hopes to remove the FDA stance that CBD needs testing before approval in dietary products due to the item being previously listed as a controlled substance based on the provision in the Federal Food, Drug, and Cosmetic Act. At the same time, some members of Congress appear unwilling to overstep the boundaries of the FDA considering the legitimate concerns of the long-term safety impact of prolonged CBD usage.We’ve delved into three U.S. companies poised to benefit from a Congress willing to direct the FDA to allow the wide use of CBD in food products. Using TipRanks’ Stock Comparison tool, we lined up the three alongside each other to give us an idea of what the Street thinks is in store for the trio in the year ahead.Charlotte's Web Holdings (CWBHF)Charlotte’s Web is the unofficial leader in the CBD space with a market valuation approaching $1 billion after this rally. Despite disappointing Q3 results due to national retailers pulling back from offering hemp-infused edibles, the company still generated $25 million in sales.The stock has soared off the lows near $6 recently to top $9 in a matter of days this week. CWH traded above $25 back in the Summer when the market expected the CBD company to hit 2020 revenue targets reaching $350 million.The company has a lot at stake with whether the FDA approves CBD infused in food and supplements. Management estimated that small independent retailers willing to sell the full scope of their products obtained up to 85% of sales from the items questioned by the FDA.CWH has seen retail doors reach the 10,000 level. Unfortunately, the growth is mainly within the FDM channel unwilling to risk ire with the FDA due to the lack of regulatory clarity on ingestible products.The CBD producer recently raised about $50 million in an equity offering at $10 per share plus warrants exercisable in the future. CWH is best positioned to expand when the FDA no longer stands in the way.All in all, CWH sells for a bargain $8.72, a price that is especially attractive when the upside potential is taken into account. The average price target, $14.11, indicates room for over 60% growth to the upside in this stock. The Strong Buy analyst consensus is based on 6 "buy" and 1 "hold" ratings set in the last two months. (See CWH's price targets and analyst ratings on TipRanks)CV Sciences (CVSI)CV Sciences has a robust retail distribution count at 5,435 stores as of September 30 with plenty of national retailers signed up. As with CWH, the company saw Q3 sales hit by the FDAs view on CBD products while the retail store count topped 5,700 in November.Despite the retail store increase, sales declined in the September quarter to only $12.6 million. The revenue miss pushed CV Sciences into a $1.1 million net loss.The company ended the quarter with a cash balance of $14.4 million and a diluted share count of nearly 116 million shares. CVI Sciences guided to 2019 revenues in the range of $55 million to $57 million suggesting December revenues of only $11.6 million.Analysts expect a ramp to 2020 sales of $75 million, but the target is highly in question considering the FDA restrictions and the competitive market. Last year, analysts were predicting sales of around $120 million in 2020 as an indication of where the growth potential exists without the FDA blocking key food and dietary supplements from the market.Judging from the consensus breakdown, it has been relatively quiet when it comes to analyst activity. Over the last three months, only 3 analysts have reviewed the CBD oil maker. All three are bullish, making the consensus a Strong Buy. On top of this, the $4.00 average price target puts the upside potential at 230%. (See CV Sciences' stock-price forecast and analyst ratings)cbdMD (YCBD)cbdMD is a prime example of a company impacted by the delayed CBD market despite revenue growth. After a bad Q3 report in December, the company was recently forced into selling 16.0 million shares with an over-allotment of 2.4 million shares at $1.00 per share, raising ~$18.4 million before fees. The stock traded above $6 for a couple of months in 2019 so raising funds at this level was very dilutive for shareholders with only ~45 million shares outstanding prior to the offering.For the FQ4 ended September 30, cbdMD reported sales of $9.5 million and a total of $23.7 million for the fiscal year. The company suggests pro-forma sales for the year of $26.8 million as sales slowly ramped during the year with $8.0 million in the prior quarter.While sales increased during the year, gross margins for FQ4 were down to only 56.7% versus 63.0% in the prior quarter. In addition, the company cut back FY20 revenue guidance to between $62 million and $70 million, down from prior guidance of $80 million to $90 million.The problem here is the substantial operating loss from operations. cbdMD had annual gross profits of only $14.5 million with operating expenses up at $28.9 million. The management team forecast reaching positive cash flows by October and this goal is clearly very important considering the recent equity raise.For now, the restrictive FDA and unknown CBD bill outcome makes the stock too risky. cbdMD will greatly benefit from a less restrictive FDA, but investors must wait on this one until the risk is removed with actual passage of a bill.To find good ideas for cannabis stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
cbdMD, Inc. a nationally recognized consumer cannabidiol (CBD) brand (NYSE American: YCBD), and the Registrar at National Day Calendar, have declared January as "National CBD Month."
Paw CBD, a division of cbdMD, Inc. (NYSE American: YCBD), a nationally recognized consumer cannabidiol (CBD) brand, was awarded an accolade given by one of the top publications in the pet industry. Pet Business Magazine named Paw CBD's Calming Turkey CBD Soft Chews as a top CBD product for pets in their dog calming aids category.